Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Results of the Hyper-CVAD Regimen in Elderly Acute Lymphocytic Leukemia (ALL)

Susan O’Brien, M.D., Deborah Thomas, MD, Farhad Ravandi-Kashani, Stefan Faderl, Sherry Pierce, Hagop Kantarjian

Blood (2008) 112 (11): 3954.

https://doi.org/10.1182/blood.V112.11.3954.3954

Published: 2008

Journal Articles

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

Susan O’Brien, M.D., Deborah Thomas, MD, Farhad Ravandi-Kashani, Stefan Faderl, Jorge Cortes, Gautam Borthakur, Sherry Pierce, Guillermo Garcia- Manero, Hagop Kantarjian

Blood (2008) 112 (11): 3966.

https://doi.org/10.1182/blood.V112.11.3966.3966

Published: 2008

Journal Articles

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Gautam Borthakur, MD, Marcos de Lima, MD, Hagop Kantarjian, MD, Lianchun Xiao, MS, Leandro de Padua Silva, MD, Guillermo Garcia-Manero, MD, Sergio Giralt, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Richard Champlin, MD

Blood (2008) 112 (11): 3302.

https://doi.org/10.1182/blood.V112.11.3302.3302

Published: 2008

Journal Articles

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Jean-Pierre Issa, Ryan Castoro, Farhad Ravandi-Kashani, Stefan Faderl, Xuelin Huang, Elihu Estey, Gautam Borthakur, Gail Morris, Guillermo Garcia-Manero, Hagop M Kantarjian

Blood (2008) 112 (11): 228.

https://doi.org/10.1182/blood.V112.11.228.228

Published: 2008

Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.

Blood (2007) 110 (11): 1851.

https://doi.org/10.1182/blood.V110.11.1851.1851

Published: 2007

Journal Articles

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

Nitin Jain, MD, Gloria N. Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Guillermo Garcia-Manero, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Gautam Borthakur, MD, Susan O’Brien, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 2858.

https://doi.org/10.1182/blood.V110.11.2858.2858

Published: 2007

Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3543.

https://doi.org/10.1182/blood.V110.11.3543.3543

Published: 2007

Journal Articles

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Susan O’Brien, MD

Blood (2007) 110 (11): 2824.

https://doi.org/10.1182/blood.V110.11.2824.2824

Published: 2007

Journal Articles

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Jorge Cortes, MD, Stefan Faderl, MD, Farhad Ravandi-Kashani, MD, William Wierda, MD, PhD, Alma Rodriguez, MD, Luis Fayad, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2825.

https://doi.org/10.1182/blood.V110.11.2825.2825

Published: 2007

Journal Articles

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Deborah Thomas, MD, Jorge Cortes, MD, Steven M. Kornblau, MD, Zeev Estrov, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, DVM, Francis Giles, MD, Xuelin Huang, PhD, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 159.

https://doi.org/10.1182/blood.V108.11.159.159

Published: 2006

Journal Articles

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

Gautam Borthakur, Farhad Ravandi-Kashani, Jorge Cortes, Elias Jabbour, Stefan Faderl, Susan O’Brien, Srdan Verstovsek, Guillermo Garcia-Manero, Beth Ann Newman, Francis Giles, Jean-Pierre Issa, Hagop M. Kantarjian

Blood (2006) 108 (11): 518.

https://doi.org/10.1182/blood.V108.11.518.518

Published: 2006

Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.

Blood (2006) 108 (11): 2612.

https://doi.org/10.1182/blood.V108.11.2612.2612

Published: 2006

Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.

Blood (2006) 108 (11): 2652.

https://doi.org/10.1182/blood.V108.11.2652.2652

Published: 2006

Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL).

Gautam Borthakur, Susan O’Brien, Farhad Ravandi-Kashani, Francis Giles, Aaron D. Schimmer, Jean Viallet, Hagop Kantarjian

Blood (2006) 108 (11): 2654.

https://doi.org/10.1182/blood.V108.11.2654.2654

Published: 2006

Journal Articles

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

Elias Jabbour, Susan O’Brien, Farhad Ravandi-Kashani, Jorge Cortes, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Francis Giles, Lourdes Zanoria, Jan Davisson, Jean-Pierre Issa, Hagop M. Kantarjian

Blood (2006) 108 (11): 2655.

https://doi.org/10.1182/blood.V108.11.2655.2655

Published: 2006

Journal Articles

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

Stefan Faderl, MD, William G. Wierda, MD PhD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Michelle Detry, PhD, Hagop M. Kantarjian, MD, Brandi O’Neal, RN, Michael J. Keating, MB BS

Blood (2006) 108 (11): 2836.

https://doi.org/10.1182/blood.V108.11.2836.2836

Published: 2006

Journal Articles

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Stefan Faderl, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, Michael Andreeff, MD, PhD, Laurie A. Letvak, MD, Dan Jones, MD, PhD, Richard Champlin, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 284.

https://doi.org/10.1182/blood.V108.11.284.284

Published: 2006

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

NARROW

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Results of the Hyper-CVAD Regimen in Elderly Acute Lymphocytic Leukemia (ALL)

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL).

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL).

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only